A detailed history of Wedmont Private Capital transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Wedmont Private Capital holds 8,095 shares of BMY stock, worth $471,371. This represents 0.02% of its overall portfolio holdings.

Number of Shares
8,095
Previous 7,096 14.08%
Holding current value
$471,371
Previous $294,000 42.18%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$39.66 - $51.75 $39,620 - $51,698
999 Added 14.08%
8,095 $418,000
Q2 2024

Jul 15, 2024

SELL
$40.25 - $52.99 $74,744 - $98,402
-1,857 Reduced 20.74%
7,096 $294,000
Q1 2024

Apr 10, 2024

SELL
$47.98 - $54.4 $34,353 - $38,950
-716 Reduced 7.41%
8,953 $485,000
Q4 2023

Jan 09, 2024

SELL
$48.48 - $57.85 $220,729 - $263,391
-4,553 Reduced 32.01%
9,669 $496,000
Q3 2023

Oct 10, 2023

BUY
$57.89 - $64.73 $9,783 - $10,939
169 Added 1.2%
14,222 $825,000
Q2 2023

Jul 17, 2023

SELL
$63.71 - $70.74 $65,175 - $72,367
-1,023 Reduced 6.79%
14,053 $898,000
Q1 2023

Apr 11, 2023

BUY
$65.71 - $74.53 $35,811 - $40,618
545 Added 3.75%
15,076 $1.04 Million
Q4 2022

Jan 09, 2023

BUY
$68.48 - $81.09 $185,717 - $219,916
2,712 Added 22.95%
14,531 $0
Q3 2022

Oct 03, 2022

BUY
$0.13 - $76.84 $12 - $7,376
96 Added 0.82%
11,819 $840,000
Q2 2022

Jul 11, 2022

BUY
$72.62 - $79.98 $153,228 - $168,757
2,110 Added 21.95%
11,723 $903,000
Q1 2022

Apr 05, 2022

BUY
$61.48 - $73.72 $189,112 - $226,762
3,076 Added 47.06%
9,613 $709,000
Q4 2021

Jan 14, 2022

BUY
$53.63 - $62.52 $350,579 - $408,693
6,537 New
6,537 $422,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Wedmont Private Capital Portfolio

Follow Wedmont Private Capital and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wedmont Private Capital, based on Form 13F filings with the SEC.

News

Stay updated on Wedmont Private Capital with notifications on news.